Conditions: Non Hematologic Cancers
Keywords: Focal Adhesion Kinase inhibitor FAK inhibitor Cancer Stem Cells CSC
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The purpose of this study is to assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063).

Detailed description:

Arms:
arm 1: Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.

Interventions: intervention 1: Defactinib
Intervention descriptions: intervention 1: None

Protocol document: